kabutan

Medrx Co.,Ltd.(4586) Summary

4586
TSE Growth
Medrx Co.,Ltd.
114
JPY
-2
(-1.72%)
Jan 29, 3:30 pm JST
0.74
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
114.3
Jan 29, 3:24 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.25
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
115 JPY 0.75 USD
Previous Close Jan 28
116 JPY 0.76 USD
High Jan 29, 9:00 am
115 JPY 0.75 USD
Low Jan 29, 9:03 am
112 JPY 0.73 USD
Volume
465,300
Trading Value
0.05B JPY 0.35M USD
VWAP
113.44 JPY 0.74 USD
Minimum Trading Value
11,400 JPY 74 USD
Market Cap
6.77B JPY 0.04B USD
Number of Trades
136
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
859
1-Year High Sep 29, 2025
32,058
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 6,239,900
Jan 16, 2026 0 6,315,200
Jan 9, 2026 0 6,286,100
Dec 26, 2025 0 6,443,300
Dec 19, 2025 0 6,901,800
Company Profile
Medrx Co., Ltd. is a drug discovery venture company with strengths in transdermal drug delivery system technologies and microneedle array technology.
Sector
Pharmaceuticals
Medrx Co., Ltd. aims to create new value-added pharmaceuticals through its proprietary transdermal drug delivery system technologies, primarily ILTS and NCTS. These technologies maximize drug efficacy, reduce side effects, and enable drug administration to patients who have difficulty with oral intake. One of the company's main development pipelines, MRX-5LBT for the treatment of post-herpetic neuralgia, received a Complete Response Letter from the FDA in September 2023. Other pipelines include MRX-4TZT for spastic paralysis, MRX-9FLT for central analgesic, and MRX-7MLL for Alzheimer's disease. Additionally, the company is developing microneedle technology, a vaccine delivery device that allows for painless self-administration. Medrx Co., Ltd. is expanding globally through its U.S. subsidiary and is promoting development and commercialization through partnerships with pharmaceutical companies and other entities.